Abstract
Many reports of Autologous Stem Cell Transplant (ASCT) in patients with multiple myeloma are available in the literature to determine safety for patients with hemodialysis-dependent End-Stage Renal Disease (ESRD). However, very few report the safety of high-dose chemotherapy followed by ASCT in the context of lymphoma.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Open Journal of Clinical & Medical Case Reports
Paper Title
Journal
Date
